The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis
- 1 July 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 22 (8) , 1014-1029
Abstract
Advances in genomics and proteomics aid the identification of genes associated with various diseases. Genome-Wide Association Studies (GWAS) have identified multiple loci as risk alleles for susceptibility to Rheumatoid Arthritis (RA). A bisection of RA risk can be attributed to genetic factors. Over 100 associated genetic loci that encompass immune regulatory factors have been found to be linked with RA. Aberrant Single Nucleotide Polymorphisms (SNPs) and alternative splicing mechanisms in such loci induce RA. These aberrations are viewed as potential therapeutic targets due to their association with a multitude of diseases. This review presents a few imperious genes whose alterations can cause severe bone deformities culminating in RA.Keywords
Funding Information
- Department of Science and Technology, SERB (EEQ/2017/000466)
This publication has 168 references indexed in Scilit:
- Alternative Splicing for Diseases, Cancers, Drugs, and DatabasesThe Scientific World Journal, 2013
- Lymphoid tyrosine phosphatase and autoimmunity: human genetics rediscovers tyrosine phosphatasesSeminars in Immunopathology, 2010
- The role of tenascin-C in tissue injury and tumorigenesisJournal of Cell Communication and Signaling, 2009
- Human glucocorticoid receptor isoform β: recent understanding of its potential implications in physiology and pathophysiologyCellular and Molecular Life Sciences, 2009
- FOXP3 and the regulation of Treg/Th17 differentiationMicrobes and Infection, 2009
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's diseaseNature Genetics, 2008
- Differential regulation and properties of MAPKsOncogene, 2007
- De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signallingNature, 2004
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002